← All trials
NCT04606394
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 2, 2020
- Primary completion
- Jul 30, 2021
- Completion date
- Dec 31, 2021
- First posted
- Oct 28, 2020
- Last posted
- Dec 4, 2020
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Pulmonary Research Institute of Southeast MichiganLead sponsor
- Pulmonary Research Institute of Southeast MichiganOverall official - principal investigator
- GlaxoSmithKlineCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.